Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy

Type de document :
Communication dans un congrès
the 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. Annals of Oncology, Volume 28, Issue suppl_5, 28 (suppl_5), 2017, Abstract Book of the 42nd ESMO Congress (ESMO 2017) 8–12 September 2017, Madrid, Spain. 〈https://academic.oup.com/annonc/article/28/suppl_5/mdx369.155/4108858/773TiPPRODIGE-51-GASTFOX-Phase-III-randomised〉. 〈10.1093/annonc/mdx393.007〉
Liste complète des métadonnées

https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01632524
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : vendredi 10 novembre 2017 - 12:47:38
Dernière modification le : mardi 6 février 2018 - 15:56:21

Identifiants

Citation

C. Gallois, J. Taieb, D. Le Corre, K. Le Malicot, J. Tabernero, et al.. Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy . the 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. Annals of Oncology, Volume 28, Issue suppl_5, 28 (suppl_5), 2017, Abstract Book of the 42nd ESMO Congress (ESMO 2017) 8–12 September 2017, Madrid, Spain. 〈https://academic.oup.com/annonc/article/28/suppl_5/mdx369.155/4108858/773TiPPRODIGE-51-GASTFOX-Phase-III-randomised〉. 〈10.1093/annonc/mdx393.007〉. 〈hal-01632524〉

Partager

Métriques

Consultations de la notice

18